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ABSTRACT Surface expression of the common vertebrate sialic acid (Sia) N-acetyl-
neuraminic acid (Neu5Ac) by commensal and pathogenic microbes appears structur-
ally to represent “molecular mimicry” of host sialoglycans, facilitating multiple mecha-
nisms of host immune evasion. In contrast, ketodeoxynonulosonic acid (Kdn) is a more
ancestral Sia also present in prokaryotic glycoconjugates that are structurally quite dis-
tinct from vertebrate sialoglycans. We detected human antibodies against Kdn-termi-
nated glycans, and sialoglycan microarray studies found these anti-Kdn antibodies to
be directed against Kdn-sialoglycans structurally similar to those on human cell surface
Neu5Ac-sialoglycans. Anti-Kdn-glycan antibodies appear during infancy in a pattern
similar to those generated following incorporation of the nonhuman Sia N-glycolyl-
neuraminic acid (Neu5Gc) onto the surface of nontypeable Haemophilus influenzae
(NTHi), a human commensal and opportunistic pathogen. NTHi grown in the presence
of free Kdn took up and incorporated the Sia into its lipooligosaccharide (LOS).
Surface display of the Kdn within NTHi LOS blunted several virulence attributes of the
pathogen, including Neu5Ac-mediated resistance to complement and whole blood kill-
ing, complement C3 deposition, IgM binding, and engagement of Siglec-9. Upper air-
way administration of Kdn reduced NTHi infection in human-like Cmah null (Neu5Gc-
deficient) mice that express a Neu5Ac-rich sialome. We propose a mechanism for the
induction of anti-Kdn antibodies in humans, suggesting that Kdn could be a natural
and/or therapeutic “Trojan horse” that impairs colonization and virulence phenotypes
of free Neu5Ac-assimilating human pathogens.
IMPORTANCE All cells in vertebrates are coated with a dense array of glycans often
capped with sugars called sialic acids. Sialic acids have many functions, including serving
as a signal for recognition of “self” cells by the immune system, thereby guiding an
appropriate immune response against foreign “nonself” and/or damaged cells. Several
pathogenic bacteria have evolved mechanisms to cloak themselves with sialic acids and
evade immune responses. Here we explore a type of sialic acid called “Kdn” (ketodeoxy-
nonulosonic acid) that has not received much attention in the past and compare and
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contrast how it interacts with the immune system. Our results show potential for the
use of Kdn as a natural intervention against pathogenic bacteria that take up and coat
themselves with external sialic acid from the environment.
KEYWORDS Kdn, nontypeable Haemophilus influenzae (NTHi), sialic acid, Neu5Ac,
molecular mimicry, antibody, bacterial pathogenesis, CMAH, glycobiology
Glycan chains on vertebrate cell surfaces and secreted molecules are often cappedby nine-carbon backbone monosaccharides called sialic acids (Sias) (1). The unique
location, cellular occurrence, and biochemical properties of Sias have imparted impor-
tant functions in normal and pathophysiology of humans, including interactions with
microorganisms, both beneficial and pathogenic (1, 2). Common members of this fam-
ily include N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid (Neu5Gc), and
2-keto-3-deoxy-D-glycero-D-galacto-nonulosonic acid (Kdn). While Neu5Ac and Neu5Gc
are prominent in mammals and extensively studied, advancements in Kdn research
have been slow and limited since its discovery (3).
Kdn is most abundant in glycoconjugates of cold-blooded vertebrates, and while
Sias are generally absent in plants (except for some evidence in green algae) (4, 5),
Kdn-glycoconjugates have been reported in microalgae such as Emiliania huxleyi (6)
and Prymnesium parvum (7). The most common deuterostome Sia, Neu5Ac, is biosyn-
thesized from condensation of N-acetyl-D-mannosamine-6-phosphate (or N-acetylman-
nosamine in prokaryotes) with phosphoenolpyruvate. In an analogous manner, Kdn is
formed from mannose-6-phosphate and phosphoenolpyruvate condensation (8, 9).
Kdn is resistant to most bacterial and viral sialidases that cleave Neu5Ac from sialogly-
coconjugates (10, 11). However, sialidases that can release glycoconjugated Kdn as well
as Neu5Ac have been identified in loach liver (10), rainbow trout tissues (11), and bacte-
rium Sphingobacterium multivorum (12, 13). Kdn-specific sialidases lacking activity toward
Neu5Ac-glycoconjugates have been reported in Aspergillus fumigatus (14), while the star-
fish Asterina pectinifera possesses separate Neu5Ac and Kdn sialidases (15). The nine-car-
bon Kdn is distinct from eight-carbon monosaccharide 3-deoxy-D-manno-oct-2-ulosonic
acid (Kdo) (16), which is an integral component of Gram-negative bacterial lipopolysaccha-
rides (17) and present in some algae (18) and cell walls of higher plants (19–21) (see
Table S1 in the supplemental material). Moreover, unlike Kdn, Kdo is widely studied (16,
22) including for its role in host-bacterium interaction (23).
Mammalian cell surfaces are frequently covered with Neu5Ac- and Neu5Gc-ter-
minated glycoconjugates, except in humans, New World monkeys, mustelids (e.g.,
ferrets), and pinnipeds (e.g., seals), which express only Neu5Ac (24–26) due to inde-
pendent loss-of-function events involving CMAH. Cmah encodes cytidine mono-
phosphate (CMP)-Neu5Ac hydroxylase, an enzyme that converts CMP-Neu5Ac to
CMP-Neu5Gc, yielding sialoglycomes containing both Neu5Ac and Neu5Gc. Neu5Ac
is also present in some bacteria, but prokaryotes do not naturally synthesize
Neu5Gc (27, 28). In comparison, Kdn-glycoconjugates have been reported in certain
algae (6, 7, 29) and in some bacteria like Streptomyces sp. strain MB-8, Streptomyces
sp. strain VKM Ac-2124 (30, 31), Sinorhizobium fredii SVQ293 (32), and Klebsiella
ozaenae serotype K4 (33).
Free Kdn has been reported in human fetal red blood cells (RBCs) (34, 35) and
in human malignancies like ovarian, prostate, and throat cancers (35–37). While
there is no conclusive evidence for glycosidically bound Kdn-glycoconjugates in
normal human tissues, the human Sia synthase enzyme can nevertheless produce
both Neu5Ac and Kdn from N-acetyl-D-mannosamine-6-phosphate and mannose-
6-phosphate, respectively (38). Although the functions of Kdn remain unclear, the
conservation of Kdn synthase in vertebrates, including humans, suggests physio-
logical relevance yet to be understood (39–43). Antibodies against the nonhuman
Sia, Neu5Gc, have been extensively studied (44, 45), and play important roles in
“xenosialitis” associated with different human cancers and pathophysiologies (46,
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47). Given the existence of Kdn in humans, we therefore speculate a broader func-
tionality of this Sia, and the antibodies it might generate, than currently known.
Here we sought to expand our understanding of Kdn and explore its role in host-
pathogen interactions. We found that humans develop anti-Kdn antibodies early in the
first year of life correlating with the appearance of anti-Neu5Gc antibodies. An obligate
human upper respiratory tract commensal and opportunistic pathogen, nontypeable
Haemophilus influenzae (NTHi), may contribute to anti-Neu5Gc antibody generation in
humans (48). Using NTHi as a representative model for any Sia-assimilating bacteria
and its Neu5Ac-related pathways as “proof of principle,” we showed free Kdn was
taken up and displayed on surface sialoglycans of lipooligosaccharide (LOS), sensitizing
the bacterium to killing by complement in normal serum and whole blood. Unlike the
protective value of host Neu5Ac incorporation and display, the presence of Kdn on
LOS did not disrupt complement C3 or IgM antibody deposition. Finally, we adminis-
tered Kdn to Cmah null (Cmah2/2) mice expressing a human-like sialoglycan profile to
provide evidence that free Sia plays important roles in bacterial Sia uptake and infec-
tion in vivo.
RESULTS
Unlike Neu5Ac, Kdn-containing glycan structures found in prokaryotes do not
mimic vertebrate glycoconjugates. While the significance of microbial Neu5Ac-gly-
can interaction with humans has been extensively studied (49), a comprehensive
account and appreciation of prokaryotic sialoglycan structures are lacking. To better
understand Sia evolution in prokaryotes, we surveyed available bacterial glycan data-
bases for Neu5Ac- and Kdn-containing glycans (50). Of more than 400 different
Neu5Ac-containing glycan structures currently described in bacterial LOS or capsular
polysaccharides, about 82% contain Neu5Ac as the terminal monosaccharide, includ-
ing 16% present as polymers of Neu5Ac residues called polysialic acid (Fig. 1A; see also
File S1 in the supplemental material). Sias are the more recently evolved members of a
diverse family of nine-carbon monosaccharides called nonulosonic acids (NulOs), with
the term “sialic acid” reserved for NulOs present in members of Deuterostome lineages
and their associated microorganisms (51). The appearance of Neu5Ac in bacteria may
be a result of convergent evolution (52, 53). While genes involved in NulO metabolism
are widespread in prokaryotic genomes (51), we observed Neu5Ac largely in bacterial
commensals of human microbiome or pathogens involved in human diseases (column
B in File S1). Furthermore, the majority of terminal Neu5Ac in bacterial structures is
linked to N-acetyllactosamine (Fig. 1B), which mimics a common vertebrate sialoglycan
structure (54). All these findings are consistent with host molecular mimicry. In con-
trast, we found Kdn in about 50 different prokaryotic polysaccharide structures, mostly
in ubiquitous environmental bacteria, not in the human microbiome or those associ-
ated with infectious diseases (column B in File S2). Unlike Neu5Ac, bacterial Kdn is
mostly (about 88%) present as internal residue in polysaccharide glycans (Fig. 1A and
B; see also Files S1 and S2). These Kdn-containing glycans share few similarities with
vertebrate sialoglycoconjugates, although Kdn is sometimes linked to galactose in the
sialoglycan (Fig. 1B). Overall, available structural information in glycan databases sug-
gests that Kdn evolution does not fit the paradigm in which prokaryotic Neu5Ac is
likely a convergent evolutionary strategy to mimic host sialoglycoconjugates and sub-
vert immune responses (51). Rather, the occurrence of Kdn as a core component of
several bacterial polysaccharides indicates a more ancestral Sia, integrated into pro-
karyotic glycomes and retained only in some eukaryotic taxa.
Circulating human anti-Kdn antibodies are directed against Kdn-epitopes of
vertebrate sialoglycoconjugates. Human cells are decorated with terminal Neu5Ac
and its derivatives, the only Sia class that they can synthesize and incorporate into their
sialoglycoconjugates. As a result of the Cmah2 deletion mutation, humans cannot pro-
duce endogenous Neu5Gc (24, 55); however, humans can assimilate dietary Neu5Gc
and display it on their glycoconjugates (48). Unlike these two common mammalian
Sias, Kdn is normally present in humans only as free monosaccharide, except possibly
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in some cancers (34, 35). Given the apparent lack of glycosidically linked Kdn, we were
intrigued to find the presence of anti-Kdn antibodies in healthy human sera. To probe
the corresponding epitopes of human anti-Kdn antibodies, we used an extensive array
of diverse glycans displaying Sia as the terminal residue (Fig. 2) (56, 57). These chemo-
enzymatically synthesized glycans represent oligosaccharide sequences commonly
found terminating natural glycoconjugates. Commercially available pooled human in-
travenous immunoglobulins (IVIG) bound to sialoglycans on the microarray, revealing
antibodies against several Kdn-terminating glycans (Fig. 2A, last column). However, the
overall anti-Kdn antibody prevalence in IVIG was much lower than those against
Neu5Gc-terminated glycans (Fig. 2A). In sera from 24 randomly selected healthy adults
(S-18 to S-81), both males and females, various levels of antibodies against Neu5Gc-
and Kdn-epitopes were identified with minimal, if any, reactivity against Neu5Ac-gly-
cans (Fig. 2A). To confirm Sia specificity and eliminate cross-reactivity against underly-
ing glycans, we also looked for antibodies against asialoglycan-epitopes representing
underlying glycans of the sialoglycan probes (Fig. 2A). Notably, the sialoglycan micro-
array interactions indicate that antigenic determinants of these human anti-Kdn anti-
bodies are structures (Fig. 2B) similar to mammalian glycoconjugates that normally
contain Neu5Ac as the terminal Sia and are present on surfaces of human cells and
human-associated microorganisms (54). While the complete antigenic repertoire of
anti-Kdn-glycan antibodies is yet to be revealed, our microarray data suggest molecu-
lar mimicry of human Neu5Ac-sialoglycoconjugates is involved in the generation of
the antibodies (54).
FIG 1 Structural evidence of molecular mimicry in Neu5Ac-containing, but not Kdn-containing,
glycans in prokaryotes. (A) The occurrence of Neu5Ac- and Kdn-containing glycan structures in
prokaryotes was determined by searching the open access database csdb.glycoscience.ru. The
percent quantification is based on data compiled from 432 different Neu5Ac-containing and 55
Kdn-containing prokaryotic structures currently listed in the database. While Neu5Ac is present
mainly as the terminal residue on glycan structures, Kdn is mostly an internal residue in the
prokaryotic glycans (see Files S1 and S2 in the supplemental material). The black columns represent
Sia as the terminal residue in glycan; white columns represent internal residue flanked by glycans.
(B) Schematic representation of the common monosaccharides containing Neu5Ac (left) and Kdn
(right) epitopes in lipooligosaccharide or capsular polysaccharide as obtained from the database.
The pictorial symbols used are in accordance with the Symbol Nomenclature for Graphical
Representation of Glycans (SNFG) (135) and are shown in the figure. The dotted line represents
glycosidic linkages with the remaining glycoconjugate structure.
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Human anti-Kdn-glycan antibodies appear during infancy and correlate with the
appearance of antibodies against Neu5Gc-glycans. Several antiglycan antibodies in
humans that recognize common epitopes such as galactosyl alpha1-3galactose (aGal) or
blood group antigens (anti-ABO group) are thought to develop upon immunization
by normal microbiome components (58–60). Antibodies against glycans bearing non-
human Sia Neu5Gc (48) appear during the first year of life in humans, correlating
with dietary introduction of Neu5Gc. However, the introduction of dietary Neu5Gc by
itself did not induce antibodies in human-like Cmah2/2 mice (48) suggesting that an-
tigenic triggers of these anti-Neu5Gc antibodies may arise when traces of free dietary
Neu5Gc are taken up and metabolically incorporated into surface LOS of human
commensals like NTHi (48).
In the absence of glycosidically linked Kdn on normal human tissues, we hypothe-
sized that anti-Kdn antibodies might likewise be elicited by the human microbiome.
Consistent with this notion, antigenic specificity of anti-Kdn antibodies toward Kdn-
glycoconjugates mimicking cell surface glycans in humans (Fig. 2) (54) suggests they
could be elicited by some human pathogens and/or commensals that use Neu5Ac in
molecular mimicry of the host. In this model, anti-Kdn antibodies would appear
FIG 2 Antigenic specificity of the human anti-Kdn glycan antibodies. Heatmap showing the relative intensity
of the fluorophore-conjugated anti-human IgG antibodies binding with the individual glycan on the microarray.
Experiment was performed using commercially available pooled human IVIG (last column) as well as individual
(n= 24) sera. Numbers (S-18 through S-81) on the top represent individual healthy human sera. (A) Each block
represents the mean intensity of the antibody binding to the specific asialo- and sialoglycan at four independent
spots in the microarray. Glycans are grouped by their nonsialylated (asialo-), Neu5Ac-, Neu5Gc-, and Kdn-
terminating structures. The complete list of glycan structures represented is provided in panel B. Each column
represents the relative binding preference of IgG antibodies in the corresponding serum toward the specific
glycan epitopes. The color code of the heatmap is indicated, and the corresponding glycan in each row matched
with the list in panel B.
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following postnatal seeding of newborns with the microbiome from their mother and/
or the environment (61–64). To determine when antibodies against Kdn-epitopes first
appear, we performed sialoglycan microarray binding assays with a previously
reported collection of sera (n = 15) obtained at birth and at 3, 6, and 12months of
age (48). We also investigated sialoglycan binding of sera from nine out of 15
matched mothers and healthy adults (n = 24, control) (Fig. 3). Sera were tested for
interaction with sialoglycoconjugates presenting terminal Kdn in different a-link-
ages with underlying glycans as in Fig. 2. We observed IgG antibodies against Kdn-
glycans in cord blood, but their abundance dropped at 3months of age, suggesting
that they arose from transplacental transfer of maternal antibodies during preg-
nancy (65). Anti-Kdn IgG antibodies reappeared by 6months of age and within the
first year of life attain levels similar to those in adults (Fig. 3A). The dynamics of
anti-Kdn antibodies are similar to previously reported antibodies against the
Neu5Gca2–6Lacb-epitope, appearing during the first year (48) and coinciding with
the course of microbiome establishment in infants (66). Here we expanded on that
observation to show that anti-Neu5Gc IgG antibodies against diverse Neu5Gc-epi-
topes are generated in this time window (Fig. 3B). We also found that while the
FIG 3 Appearance of anti-Kdn IgG and IgM antibodies in the first year of human life. Binding of human sera
to Kdn- and Neu5Gc-containing glycan epitopes was determined by sialoglycan microarray binding assay. Sera
were obtained from cord blood (n= 15) and the child at 3, 6, and 12 months old and from 9 out of the 15
matched mothers in their third trimester of pregnancy. Control represents sera from blood from healthy
human donors (both male and female) (n= 24). The average relative fluorescence unit (RFU) in arbitrary units
(A.U.) against terminal Kdn (A and C) or Neu5Gc (B and D) containing glycan epitopes with underlying
structures similar to vertebrate glycoconjugates are shown. Each dot represents the mean RFU values against
all the Kdn (A and C)- or Neu5Gc (B and D)-containing glycans, respectively, for individual serum. (A to D)
Relative abundance of the human IgG (A and B) and IgM antibodies (C and D) against the corresponding
sialoglycoconjugates. Statistical significance was evaluated using one-way ANOVA with Tukey’s multiple
comparison test. The mean 6 standard error of the mean (SEM) (error bars) values and the adjusted P values
are shown in the figure.
Saha et al. ®
January/February 2021 Volume 12 Issue 1 e03226-20 mbio.asm.org 6
 on M






















kinetics of anti-Kdn IgG antibody appearance are similar to those of anti-Neu5Gc
antibodies, the relative serum abundance of the former is much lower, perhaps
reflecting reduced availability or antigenicity of natural Kdn-epitopes compared to
Neu5Gc-epitopes in humans.
To ascertain whether anti-Kdn-glycan antibodies are generated postnatally fol-
lowing antigen presentation or are “natural” antibodies encoded in germ line (67),
we further looked for IgM in the infant and adult sera. Unlike IgG, maternal IgM
antibodies fail to cross the placenta, and the presence of IgM antibody in cord
blood would suggest they were generated by the newborn prior to any antigen ex-
posure. Anti-Kdn-glycan IgM antibodies did not appear in infant blood until
6 months of age and gradually increased thereafter (Fig. 3C). IgM antibodies against
Kdn-glycans were also present in mothers suggesting their persistence in adults. By
12months, these antibodies reached maternal levels corresponding to establish-
ment of the normal microbiome in different niches throughout human body (63,
64). Appearance of IgM antibodies against Neu5Gc-glycoconjugates showed similar
profiles (Fig. 3D). Thus, antibodies against Kdn-epitopes are not germ line-encoded
“natural” antibodies (68) but instead are generated by the adaptive immune system
of the newborn following antigen exposure.
Free exogenous Kdn can be incorporated into NTHi surface LOS. A contributing
factor to the development of antibodies against nonhuman Sia Neu5Gc is proposed to
be presentation of glycosidically linked Neu5Gc on surface LOS of uniquely human
bacteria NTHi (48). Appearance of anti-Kdn antibodies shows a profile similar to the
occurrence of antibodies against NTHi surface oligosaccharides (48) and coincides with
the onset of NTHi colonization in the newborn (61, 66, 69). To test our hypothesis that
the natural microbiome may contribute to generation of anti-Kdn antibodies, we uti-
lized NTHi as a model exogenous Sia-assimilating microbe. Clinical isolate NTHi 2019
(70) was grown in the presence of 100mM free Sias, and Kdn incorporation onto bacte-
rial LOS was measured. NTHi 2019 takes up environmental free Neu5Ac, and the result-
ing major sialylated surface glycan is Neu5Aca2-3Galb1-4GlcNAc (23, 71). To deter-
mine whether free Kdn is similarly displayed, we used the plant lectin Erythrina
cristagalli lectin (ECA) (72) that recognizes Galb1-4GlcNAc termini when they are not
capped with Sia, as confirmed by our sialoglycan microarray (see Fig. S1 in the supple-
mental material) and further ensured by a strong reduction of ECA binding in the pres-
ence of inhibitory concentrations of the competitive sugar lactose (Fig. 4A, Fig. S2A).
As expected, ECA bound NTHi 2019 when grown in Sia-free media, and the binding was
reduced after feeding and incorporation of Neu5Ac or Kdn (Fig. 4A, Fig. S2A), indicating
glycosidically linked Sia. Mouse monoclonal antibody (mAb) 3F11 specifically binds ter-
minal lactosamine of unsialylated Galb1-4GlcNAcb1-3Galb1-4Glc and is widely used to
demonstrate the surface sialylation of different bacteria, including NTHi 2019 (23).
Although the cognate disaccharide epitope is the same as ECA, mAb 3F11 is an IgM anti-
body requiring multivalent binding. As with ECA, we observed increased binding of 3F11
to NTHi 2019 grown in the absence of Sia, suggesting a reduction in its unsialylated epi-
topes upon sialylation (Fig. 4B, Fig. S2B). These results suggest that like Neu5Ac, Kdn is
displayed on NTHi 2019 surface with an underlying lactosamine structure.
Neu5Ac is an important component of NTHi LOS (23, 73). To confirm that free exog-
enous Kdn is incorporated into NTHi LOS, we purified LOS from bacteria grown in the
presence of Sia using hot phenol-water extraction (74). Purified LOS was then treated
to release glycosidically bound Sias for derivatization using 1,2-diamino-4,5-methylene-
dioxybenzene dihydrochloride (DMB) and fluorescence detection in high performance
liquid chromatography (HPLC) (75, 76). Peaks eluting at the same retention time as
Neu5Ac or Kdn were observed in LOS purified from NTHi grown in the corresponding
Sia (Fig. 4C). To determine whether free Kdn can be incorporated in the presence of
Neu5Ac, we grew NTHi 2019 with both Neu5Ac and Kdn (1:10 molar ratio). Analysis of
the purified LOS indeed showed fluorescence peaks corresponding to retention times
of both Sias (Fig. 4C). A fluorescence peak corresponding to retention time of Kdo, a
Kdn in the Evolution of Host-Pathogen Interactions ®
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key component of Gram-negative bacterial LOS, was seen in all samples confirming
LOS purification. Altogether, the data indicate that exogenous Kdn can be taken up
and incorporated in NTHi 2019 LOS in a manner similar to free Neu5Ac. Notably,
when grown without Neu5Ac, NTHi 2019 incorporates endogenously synthesized
Kdo to the terminal lactosamine on its LOS. However, the addition of exogenous
Neu5Ac to growth media is associated with the replacement of this terminal Kdo by
Neu5Ac (23).
LOS incorporation of exogenous Kdn in diverse NTHi strains. Structural hetero-
geneity of NTHi LOS prompted us to determine whether the exogenous Kdn incorpora-
tion is strain specific or can occur in others beyond NTHi 2019. We examined six differ-
ent NTHi strains, including some with well-characterized LOS structures, namely,
strains 375, 486, Rd, 1003, PittGG, and R2846 (77–81). HPLC analysis of purified LOS
from the bacteria, grown either in Neu5Ac or Kdn, showed the presence of the
FIG 4 Exogenous Kdn is taken up and displayed by NTHi on its LOS. Surface sialylation of NTHi 2019
grown in the presence or absence of Neu5Ac or Kdn was determined using plant lectin, ECA (A) and
mouse monoclonal IgM antibody 3F11 (B) in a flow cytometry-based assay. The bacteria were incubated
with biotinylated lectin at 37°C or with mouse IgM antibody (Ab) 3F11 at room temperature (RT) for
30min and then probed with fluorophore-conjugated secondary antibodies for analysis via flow
cytometry. The binding epitopes of each of the reagents are shown within the panel using the symbols
in accordance with SNFG nomenclature. “None” indicates the bacteria grown in the absence of Sia, while
“Neu5Ac” or “Kdn” indicates the presence of the corresponding Sia in growth media. ECA binding with
unsialylated bacteria done in the presence of 100mM free lactose (none with lac) was used as a control
to show the inhibition of ECA binding, since lactose is a competitive inhibitor of the lectin. Each dot
represents the mean fluorescence intensity of an independent biological experiment (n=8 for ECA; n=5
for 3F11). Fluorescence values were expressed relative to that seen with the unsialylated samples in the
same experiment to normalize for day-to-day variation. Statistical significance was determined using one-
way ANOVA with Tukey’s multiple comparison test. Bars represent the mean (SEM) for each assay (A and
B), and all the adjusted P values are shown in the figure. (C) Bacterial LOS was purified by hot phenol-
water extraction from NTHi 2019 grown in the presence or absence of one or both Sias. Representative
profiles of HPLC analysis following acid hydrolysis and DMB derivatization of purified LOS are shown. The
fluorescent intensity peaks of the individual a-keto acid are identified in the figure. Kdo represents 3-
deoxy-D-manno-oct-2-ulosonic acid, a key component of Gram-negative bacterial LOS and serves as the
internal control in each of the LOS preparations. The table below the graph shows the bacterial cultures
used to purify the corresponding LOS whose profile is shown. The presence (1) or absence (-) of the Sia
in growth media of the bacteria is indicated.
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corresponding glycosidically bound Sia on the LOS (Fig. 5). These data indicate the
ability of various NTHi strains to take up and assimilate Kdn.
NTHi uses the same machinery to take up and degrade exogenous Kdn as for
Neu5Ac. In addition to capping surface LOS, NTHi can utilize Neu5Ac as a carbon
source (71, 82, 83). Following the uptake, free Neu5Ac is degraded by bacterial Sia
lyase into N-acetylmannosamine (ManNAc) and pyruvate. ManNAc is then converted
to intermediates like glucosamine-6-phosphate and enters metabolic pathways (83).
To determine whether Kdn is metabolized in a similar manner, we first examined
growth of NTHi 2019 in the presence of Kdn (Fig. S3). The bacteria were grown in glu-
cose-augmented, RPMI-based media freshly supplemented with NAD and protopor-
phyrin IX—two essential components for NTHi growth (84). Bacterial growth in Kdn-
containing media was comparable to that in Neu5Ac. However, in the presence of its
preferred carbon source (i.e., glucose) in basal media, no significant differences in over-
all growth were observed regardless of Sia presence. Hence, we sought to specifically
determine whether Kdn can be utilized by NTHi and whether it is catabolized using a
similar machinery as for Neu5Ac. For NTHi 2019, the Neu5Ac lyase has been identified
as NanA (85). To elucidate whether NanA participates in Kdn catabolism, we employed
2019DnanA mutant (85) that lacks the lyase and cannot degrade Neu5Ac upon its
uptake. As a result of more available intact Sia, the 2019DnanA mutant strain displays
increased LOS sialylation compared to the wild-type (WT) parent strain, where Neu5Ac
is utilized for both surface sialylation and catabolism (85). Compared to WT, the lyase-
deficient mutant showed increased surface capping by both Neu5Ac and Kdn, as indi-
cated by the more pronounced reduction in ECA binding (Fig. 6A, Fig. S2C).
FIG 5 Diverse NTHi strains incorporate exogenously provided Kdn. Six NTHi strains were grown in the
presence of either Neu5Ac or Kdn and the bacterial LOS was purified by hot phenol-water extraction. HPLC
analysis of acid-hydrolyzed and DMB-derivatized LOS shows fluorescent intensity peaks corresponding to
Neu5Ac or Kdn in NTHi 375 (A), 486 (B), Rd (C), 1003 (D), PittGG (E) and R2846 (F). The individual Sia and Kdo
as the internal control of the LOS preparations are identified as in Fig. 4C. The table shows the growth
condition of bacterial cultures used to purify the LOS with (1) or without (2) the corresponding Sia added.
Kdn in the Evolution of Host-Pathogen Interactions ®
January/February 2021 Volume 12 Issue 1 e03226-20 mbio.asm.org 9
 on M






















Furthermore, purified LOS from the 2019DnanAmutant showed greater Kdn incorpora-
tion than the WT (Fig. 6B) when grown under similar conditions with equimolar Sia
concentrations.
Although Neu5Ac is important for NTHi commensalism and pathogenesis, the bac-
terium solely relies on exogenous free Neu5Ac, utilizing a tripartite ATP-independent
periplasmic transporter to sequester the Sia from its environment (85). For NTHi 2019,
components of this transporter are integral membrane protein SiaT (also known as
SiaQM) and SiaP, the membrane receptor for the ligand (i.e., Sia) binding (86, 87).
Compared to the WT, the previously reported transporter-deficient mutant 2019DsiaT
(85) remained uncapped when grown in the presence of Sia and did not show reduced
ECA binding (Fig. 6C, Fig. S4A), suggesting that ECA-epitopes have not been abolished
by Sia capping. Furthermore, no increase in Maackia amurensis lectin I (MAL I) (a plant
lectin recognizing Sia, either Neu5Ac or Kdn, a2-3-linked to underlying glycan) binding
of 2019DsiaT mutant was seen compared to unsialylated bacteria upon growth in
Neu5Ac or Kdn, suggesting the absence of sialylated MAL I-epitopes (Fig. S4B and
S4C). Together, these data show that NTHi 2019 utilizes the same enzymes (and likely
the same pathway) for the uptake and metabolism of Kdn as it does for Neu5Ac.
Unlike Neu5Ac, Kdn does not protect against serum and whole blood killing.
Incorporation of Neu5Ac on LOS allows NTHi to resist complement-mediated serum
killing (88–91). Since Kdn can be incorporated into LOS, we asked whether its presence
affected NTHi survival in human sera. Sialylated NTHi 2019 was incubated with normal
FIG 6 NTHi utilizes the same machineries for Kdn uptake and degradation as those for Neu5Ac. (A)
Presence of Sia on the surface of wild-type (WT) NTHi 2019 and lyase deletion mutant 2019DnanA
was determined using ECA binding. The bacterial treatment and data analysis are the same as
described in the legend to Fig. 4. (B) HPLC profiles of LOS purified from NTHi 2019 or 2019DnanA
grown in the presence or absence of 100mM Neu5Ac or Kdn. The relative fluorophore intensity of
the a-keto acid in arbitrary units (A.U.) present in the corresponding LOS is indicated on the y axis.
Kdo represents an internal control as in Fig. 4C. The table below the graph shows the bacterial
culture condition used to purify the corresponding LOS. (C) ECA binding assay with NTHi 2019 and
the transporter deletion mutant 2019DsiaT grown in the presence or absence of Neu5Ac or Kdn. The
dots are the same as described in the legend to Fig. 4. Statistical significance was determined using
Student t test. All the values were normalized to the values for the unsialylated samples for the
individual experiment to avoid day-to-day variation. Mean with SEM from independent experiments
(n= 4 for panel A; n= 6 for panel C) was calculated. “None” indicates the bacteria grown in the
absence of Sia, while “Neu5Ac” or “Kdn” indicates the presence of the corresponding Sia in growth
media. Adjusted P values are shown.
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human sera, and its survival was assessed. While NTHi supplemented with Neu5Ac sur-
vived serum killing, NTHi bacteria grown in Kdn were killed as readily as unsialylated
bacteria (Fig. 7A). To eliminate the possibility of inefficient sialylation with Kdn (71), we
also grew the bacteria with a lower concentration (75mM) of Neu5Ac and a higher con-
centration (1mM) of Kdn. The bacteria grown in the presence of 75mM Neu5Ac dem-
onstrated 1,000-fold better survival compared to those grown in 1mM Kdn (Fig. 7A).
Of note, growth of bacteria in the presence of both Kdn and Neu5Ac showed that the
effects of Neu5Ac (i.e., serum resistance) predominated (Fig. S5A). Sia modification of
the LOS has also been associated with bloodstream survival of invasive NTHi (92). In
survival assays with hirudin-anticoagulated human whole blood (93, 94), NTHi grown
in the presence of Kdn showed decreased survival compared to those grown in
Neu5Ac (Fig. 7B).
Presence of Kdn on NTHi LOS does not disrupt IgM antibody and C3 complement
deposition. Human serum bactericidal effects against NTHi are mainly attributed to
complement-mediated and antibody-dependent cell cytotoxicity (81, 89, 95, 96). The
presence of Sia on NTHi LOS significantly reduces IgM binding to promote resistance
against antibody-mediated immune clearance (91, 97). In contrast to IgG, IgM binding
is correlated with complement-mediated NTHi killing (98). Compared to Neu5Ac, the
presence of Kdn did not alter the deposition of IgG (Fig. S5B and S5C). However, bind-
ing of human IgM on bacterial Kdn-LOS was similar to that seen with unsialylated bac-
teria and significantly higher than observed on Neu5Ac-coated bacteria (Fig. 8A,
Fig. S5D). Several bacteria, including NTHi, have evolved efficient mechanisms to in-
hibit complement pathway activation by interacting with complement inhibitors like
factor H (FH) or by binding complement component C3 in a manner that prevents its
activation (99–101). For example, NTHi bacteria interact with domains 6 and 7 of FH to
inhibit complement activation (81, 96). While the presence of Kdn or Neu5Ac did not
alter binding of FH domains 6 and 7 (Fig. S5E and S5F), we detected increased amounts
of the C3c fragment of complement component C3 (a measure of C3b and iC3b) on
NTHi grown in the presence of Kdn relative to Neu5Ac-treated bacteria (Fig. 8B,
Fig. S5G). C3 is a key regulator of innate immunity (102), and all complement pathways
converge at the level of C3 deposition, resulting in complement activation that leads
to assembly of the membrane attack complex on bacteria. Our data suggest that in
contrast to inhibition of IgM deposition and complement activation in the presence of
Neu5Ac, the lack of inhibition of C3 fragment deposition and IgM binding to NTHi
2019 surface, grown in the presence of Kdn, keeps them susceptible to serum killing.
FIG 7 Unlike Neu5Ac, Kdn incorporation does not provide protection against serum and whole
blood killing. (A) NTHi 2019 was grown with or without Neu5Ac or Kdn and incubated in the
presence of 10% pooled normal human sera at 37°C for 30min. Percent survival was determined
from CFU counts of bacteria recovered following serum incubation relative to the inoculum. The
amounts of Sia added during bacterial growth are shown on the x axis. (B) Bactericidal effect of
hirudin-anticoagulated whole blood collected from healthy human donors is shown (n= 4). Each dot
in the figures represents the corresponding value in each experiment. Mean with SEM (n=3 for
serum killing; n= 4 for whole blood killing) and all the adjusted P values are shown. Statistical
significance was determined using one-way ANOVA with Tukey’s multiple comparison test (A) and
Bartlett’s test (B).
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Kdn-glycan epitopes do not interact with Sia-binding immunoglobulin superfamily
lectins (Siglecs). Siglecs are important immunomodulators in vertebrates, including
humans (103). NTHi interacts with Siglec-9, an immunoinhibitory receptor on account
of its immunoreceptor tyrosine-based inhibitory motif. Engaging immunoinhibitory
receptors enables bacteria to escape innate immune recognition. Siglec-9 polymor-
phisms that are less effective at dampening immune responses are associated with
exacerbations of respiratory infections and development of emphysema (104, 105).
NTHi also binds paired Siglec-5 (104) and Siglec-14 (106), and polymorphism of Siglec-
14 in humans affects inflammatory responses in chronic obstructive pulmonary disease
(104). Siglec-5 and -14 have similar extracellular ligand receptors but different cytosolic
domains to modulate inhibition and activation, respectively, of the host innate immune
response (107). To determine the effect of Kdn on the interaction of Siglecs and sialogly-
cans, we performed a sialoglycan binding assay with purified human Siglec-5, -9, and -14
(Fig. 8C). Recombinant Siglec proteins were allowed to interact with Sia-terminating gly-
cans on the microarray, and relative binding of each Siglec with Neu5Ac- or Kdn-epitopes
was determined (File S3). Siglec-9 showed a diverse range of binding with different
Neu5Ac-containing glycans and minimal binding with Kdn-epitopes except for glycans
FIG 8 Incorporated Kdn does not abolish complement C3 and IgM antibody deposition and does not
substitute for Neu5Ac in interaction with Siglecs. Bacteria grown in the presence of Neu5Ac or Kdn were
incubated with 10% pooled normal human sera for 5min at 37°C and IgM antibody (A) and complement factor
C3 (B) deposition were determined using the corresponding antibody staining in flow cytometry. For IgM
deposition, the bacteria were incubated with heat-inactivated sera. Each dot represents an independent
experiment (n= 5 for panel A and n= 8 for panel B). The data were normalized to the values for unsialylated
bacteria to eliminate the daily variation. Statistical significance was determined using one-way ANOVA with
Tukey’s multiple comparison test. Mean with SEM and adjusted P values are shown in the figure. (C) Heatmap
showing the binding of Neu5Ac- and Kdn-containing glycan epitopes to purified recombinant Fc chimeric
proteins of human Siglec-5, -9, and -14. The map represents the binding affinities of each protein toward the
corresponding glycans determined from the glycan array binding experiment. The complete list of the glycan
used are shown in File S3 in the supplemental material. Glycans with lactose underlying structure are indicated
by an asterisk. Each block corresponds to a distinct glycan with terminal Sia as indicated in the left. The color
of each block represents the mean binding intensity done in technical quadruplet. Color code is indicated
below. (D) Representative flow cytometry profiles showing Siglec-9 binding with NTHi 2019 grown in the
presence or absence of Neu5Ac or Kdn in two independent biological experiments (experiments 1 and 2).
Figure legend shows the Sia added to the bacterial growth media. “None” indicates the bacteria grown in the
absence of Sia, while “Neu5Ac” or “Kdn” indicates the presence of the corresponding Sia in growth media.
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with an underlying lactose residue (marked with asterisks in Fig. 8C). Similar results were
observed for both Siglec-5 and -14. While outer membrane proteins also contribute to
Siglec-5 and -14 binding, NTHi interaction with Siglec-9 is solely attributed to Neu5Ac
(104). We therefore confirmed the binding result of the microarray by measuring binding
of recombinant Siglec-92Fc fusion proteins to NTHi by flow cytometry. While Neu5Ac
enhanced binding of Siglec-92Fc, the presence of Kdn did not alter binding compared to
unsialylated bacteria (Fig. 8D). Since Siglec-9 showed high binding only with lactose under-
lying Kdn-glycans on the microarray (Fig. 8C), we speculate that the lack of Siglec-9 bind-
ing to Kdn-coated NTHi may either be due to the scarcity of Kdn-lactose-epitopes and/or
low affinity of Kdn for Siglec-9.
Human-like Cmah2/2 mice have higher levels of free Neu5Ac in upper airways
and are more susceptible to NTHi infection. The importance of Sia in NTHi pathoge-
nesis is well established in vitro and in vivo (108). The only known natural host of NTHi,
humans are unusual compared to most mammals (including chinchilla and mice that
have been used to study NTHi pathogenesis in vivo) because of their predominantly
Neu5Ac-rich sialoglycoconjugates. To address this difference, we infected human-like
Cmah2/2 mice with NTHi (109). Cmah2/2 mice have the same exon deletion as humans
that inactivates the CMP-Neu5Ac hydroxylase (CMAH) enzyme, resulting in a Neu5Ac-
rich sialome (110). Neu5Gc-free Cmah2/2 mice have been utilized to study uniquely
human infections and pathophysiology (109, 111, 112). Unlike WT mice that express
both Neu5Ac and Neu5Gc, Cmah2/2 mice contained only Neu5Ac in their nasal cavity,
trachea, and lungs (Fig. 9A to C). Moreover, free Neu5Ac was significantly higher in air-
ways of Cmah2/2 mice compared to WT (Fig. 9A to C). Upon intranasal challenge of WT
and Cmah2/2 mice with NTHi in two independent experiments, higher CFU counts of
bacteria were recovered from the trachea and lungs of Cmah2/2 mice compared to WT
mice 24 h postinfection (Fig. 9E and F). CFU counts recovered from nasal washes of the
two groups did not differ (Fig. 9D). Considering that the human host has a primarily
Neu5Ac-based sialoglycome, the lack of difference in the nasal cavities of WT and
Cmah2/2 mice compared to trachea and lungs further highlights the significance of
free Sia in proper understanding of NTHi in vivo infections. We did not detect bacteria
in the blood of any infected mice (data not shown).
Kdn administration reduces NTHi infection in Cmah2/2 mice. Since free Kdn
impacted different in vitro processes associated with NTHi pathogenesis, we infected
Cmah2/2 mice with NTHi and 6 h postinfection administered 5mM free Kdn intrana-
sally every 6 h. We simultaneously treated a control group with the vehicle for the
resuspension of Kdn (HBSS) to control for the physical effects of fluid instillation. Six
hours after administration of the third Kdn dose (i.e., 24 h postinfection), we sacrificed
mice and harvested the trachea and lungs. Kdn-treated mice showed significant reduc-
tion in bacterial CFU counts in the trachea (Fig. 10A), although no difference was
noticed in the lungs (Fig. 10B). Since excess Sia is mostly excreted out of the body, we
assessed persistence of free Kdn in the mice. Tissues were collected 6 h after the final
Kdn dose administration and analyzed for the presence of free Kdn relative to Neu5Ac.
HPLC analysis revealed that all tissues of the respiratory tract contain significantly
larger amounts of free Kdn compared to Neu5Ac (Fig. 10C). Moreover, sera from the
mice showed minimal increases of Kdn, suggesting a localized change in Sia concen-
trations following intranasal Kdn administration.
DISCUSSION
Here we demonstrate for the first time that humans develop antibodies against
Kdn-terminated glycoconjugates early during the first year of life. While the earliest
IgG antibodies likely represent transplacental maternal transfer, subsequent natural
immunization probably occurs through normal human microbiome. Antigenic
determinants of these antibodies closely resemble the sialoglycoconjugate presen-
tation of human cells. These surface sialoglycans represent self-associated molecu-
lar patterns (SAMPs) that are important aspects of healthy and disease processes in
the human body (113). Commensals present in different host niches such as
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Lactobacillus (114), Bifidobacterium (115), and Bacteroides (116) utilize Sias for nutri-
tion (117), pathogens like Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia
coli K1, Corynebacterium diphtheriae, Streptococcus agalactiae, Streptococcus pneu-
moniae, and Campylobacterium jejuni have evolved ways to exploit SAMPs by mo-
lecular mimicry to promote resistance against immune clearance. Extensive studies
on human microbiome have established its pivotal role in modulating immune
responses, including antibody generation (118–120). Commensals also support
host defense against pathogenic organisms (121, 122). To test a potential bacterial
contribution to anti-Kdn antibody generation, we utilized our knowledge of Sia me-
tabolism in NTHi. NTHi Sia-metabolic enzymes have evolved with Neu5Ac as the
FIG 9 Presence of free sialic acid correlates with in vivo infection of NTHi. (A to C) Free sialic acid content of
nasal wash (A), trachea (B), and lung (C) of Cmah null (open circle) and wild-type (closed circle) mice were
determined by HPLC analysis of DMB-derivatized samples of tissue collected 24 h after intranasal infection with
NTHi 2019. Statistical significance was determined by one-way ANOVA and Tukey’s multiple comparison test. (D
to F) Bacterial load postinfection was determined by the CFU counts of the bacteria from nasal wash (D),
trachea (E) and lung (F) homogenates (same samples as used for free sialic acid analysis) that were plated on
Haemophilus isolation agar. Data represent the results from two independent experiments, with each symbol
representing the value for an individual mouse (n= 9). Statistical significance was determined using the
nonparametric Mann-Whitney test. Adjusted P values are shown in the figure.
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preferred substrate (71, 87), and we observed a lower efficiency in Kdn surface
incorporation. While our current data do not entirely explain the levels of anti-Kdn
antibody present in humans, they nevertheless serve as proof of concept that Sia-
sequestering bacteria in the microbiome could act as the antigenic source to trig-
ger the generation of anti-Kdn antibodies. Our data of Kdn assimilation by different
NTHi strains (Fig. 4 and 5) as well as the promiscuity of bacterial Sia transporters
(123) further suggests that other Neu5Ac-utilizing bacteria could potentially also
assimilate Kdn from their environment.
Our work is an attempt to manipulate bacteria’s natural propensity for “molecular
mimicry” of host sialoglycans, and we used Kdn as a decoy for Neu5Ac-assimilating
pathways in NTHi to guide the immune system against the pathogen. Our data present
a unique role of Kdn contributing to the reduction of serum and whole blood survival
through the increased deposition of complement C3 and IgM antibody. Kdn incorpora-
tion could not only present new targets but also potentially uncover the nonself
(bacterial) surface epitopes, otherwise masked by Neu5Ac capping, to immune res-
ponders, thus corroborating other antimicrobial mechanisms that target non-Neu5Ac
FIG 10 Free Kdn administration reduces NTHi infection in Cmah null mice. Following NTHi 2019
infection, free Kdn was administered every 6 h intranasally to the Cmah null mice. (A and B) Twenty-
four hours postinfection, the mice were sacrificed and bacterial load of trachea (A) and lungs (B)
homogenates was determined. Control group of infected mice denoted as “vehicle” were administered
with HBSS (used as the solvent for Kdn) at the same corresponding time points as the test condition.
Statistical significance was determined using the nonparametric Mann-Whitney test. (C) HPLC analysis
of the tissue homogenates from the infected mice was performed to determine the abundance of free
Kdn relative to Neu5Ac. Statistical significance was determined using the Student’s t test. Mean 6 SEM
are shown. Data represent the results from two independent experiments, and each symbol represents
the value for an individual mouse. Adjusted P values are shown in the figure.
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structures (23, 91). The presence of Kdn reduces the engagement of Siglec-9, an inhibi-
tory Siglec widely expressed on circulating leukocytes in humans (124) that Neu5Ac-
coated microbes exploit to dampen the immune activation (125). In contrast to
Neu5Ac that bacteria including NTHi utilize to evade immune clearance, the presence
of Kdn could serve to assist the immune system in eliminating potentially pathogenic
Neu5Ac-assimilating microbes. This is further evident in the decreased CFU loads in
Cmah2/2 mice upon localized free Kdn administration (Fig. 10), which opens the possi-
bility that Kdn could interfere with microbial colonization in a Kdn-rich niche. Free Kdn
synthesis is also reported in Bacteroides thetaiotaomicron (126), a predominant human
symbiont that colonizes the naive gut around the first year of life (66). While a com-
prehensive understanding of its effect on the natural human microbiome, including
normal commensals, is yet to be ascertained, the potential implication of Kdn admin-
istration is also strengthened by the fact that, although predominantly a lower verte-
brate Sia, Kdn is naturally present in humans. Interestingly, free Kdn content in fetal
blood is about 2.4 times higher than maternal blood, and there is evidence of free
Kdn in human ovaries (34). While database mining suggests that Kdn is ancestral
compared to Neu5Ac (Fig. 1; see also Files S1 and S2 in the supplemental material),
current evidence of Kdn in bacteria is in pathogens of plants (which do not contain
any Sia) (30–32).
Altogether, while extensive studies have demonstrated the significance of Sia and
sialylation on bacterial physiology and host-pathogen interactions, the research have
mostly focused on Neu5Ac and/or Neu5Gc. This study reveals a yet unexplored aspect
of Kdn biology and suggests that it plays important roles in bacterial pathogenesis
that are still incompletely understood (Table 1). It is possible that Kdn in humans (pro-
duced by Kdn synthase) could act as natural decoy against microorganisms that utilize
host Neu5Ac. For such organisms, Kdn could also be explored as a possible therapeutic
agent.
MATERIALS ANDMETHODS
Bacterial strains and growth conditions. NTHi human clinical isolate 2019 (NTHi 2019) from
chronic obstructive pulmonary disease patient (70, 127), its transporter mutant 2019DsiaT (85), and sialic
acid lyase mutant 2019DnanA (85) were generous gifts from Michael Apicella (University of Iowa). NTHi
strains, Rd, 375, 486, 1003, PittGG, and R2846 were generously provided by Richard Moxon (Oxford
University, UK), Stephen Pelton (Boston Medical Center), and Brian J. Akerley (University of Mississippi
Medical Center) (77–81). NTHi was grown overnight from the frozen stock in chocolate II agar plate (BD
BBL) at 37°C for 16 to 18 h in the presence of 5% (vol/vol) CO2. The sialic acid-free chemically defined
medium used for bacterial growth was as described previously (85, 128). Prior to the bacterial growth,
the medium was supplemented with 1mg/ml protoporphyrin IX (Sigma-Aldrich), 1mg/ml L-histidine
(Sigma-Aldrich), and 10mg/ml b-NAD (NAD) (Sigma-Aldrich). For the mouse infections, the bacteria
were incubated in hemin (Sigma-Aldrich) and NAD-supplemented brain heart infusion (BHI) medium
(BD Biosciences) following overnight culture as described above.
Sialic acid feeding of bacteria. NTHi was grown on chocolate II agar (84) followed by incubation in
the defined media as described above. To eliminate phase variability of the LOS genes, fresh bacterial
cultures from frozen stocks were initiated prior to each experiment, and the cultures were never pas-
saged between experiments. Briefly, the day before the experiment, a fresh bacterial culture was started
from the frozen glycerol stock (maintained at –80°C) onto BD BBL chocolate II agar, grown overnight (16
to 18 h) at 37°C with 5% CO2. On the day of the experiment (i.e., after overnight growth), four or five dis-
crete colonies were incubated in broth for a starter culture. Following 2 to 3 h of growth at 37°C,
200 rpm, early log phase culture (optical density at 600 nm [OD600] = 0.075) was further incubated in the
presence or absence of 100mM Sia-Neu5Ac (Nacalai USA, Inc.), Kdn (Cayman Chemical), unless men-
tioned otherwise, for 4 to 5 h at 200 rpm in 37°C until an OD600 of 0.40 was reached. These cultures were
used in assays on that day. Surface sialylation of the bacteria used for each assay was confirmed using
ECA lectin binding assay. The sialic acid stocks were prepared in phosphate-buffered saline (PBS), pH
neutralized, filtered, and stored in aliquots at –20°C until used. Prior to the addition of Neu5Ac or Kdn,
the absence of Sia in the chemically defined media was confirmed by HPLC analysis of the DMB-derivat-
ized media.
Staining with plant lectins and 3F11 antibody. NTHi grown in the presence or absence of sialic
acid was used for lectin staining. Following Sia feeding, the bacterial culture (OD600 = 0.1) was spun at
10,000 relative centrifugal force (rcf) for 5min and washed with HBSS containing CaCl2/MgCl2. The bacte-
ria were incubated with biotinylated lectins (from Vector Laboratories)—Erythrina cristagalli lectin (ECA)
and Maackia amurensis lectin I (MAL I)—at 37°C for 30min. For 3F11 antibody (generous gift from
Michael Apicella, University of Iowa) staining, the bacteria were incubated at room temperature for
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30min. The lectins were used at the following concentration in HBSS with 0.1% BSA-ECA at 1:500 (stock,
5mg/ml), MAL I at 1:500 (stock, 2mg/ml) and 3F11 at 1:50 dilution. The binding was detected with either
streptavidin conjugated with Cy5 (Jackson ImmunoResearch Laboratories) (1:1,000) or anti-mouse anti-
body conjugated with fluorescein isothiocyanate (FITC) (Invitrogen) (1:1,000) and visualized using a BD
FACSCalibur flow cytometer. The data were analyzed using FlowJo software.
LOS purification. All NTHi strains were grown as mentioned above and incubated for 8 h (or over-
night) in the presence or absence of sialic acid. Following incubation, the bacteria were washed in PBS
and lysed by sonication and freeze-thawing. The cell lysates were incubated with Benzonase nuclease
(Millipore Sigma) and proteinase K at 37°C, and LOS was purified using hot phenol-water extraction as
described previously (129). The crude LOS was dialyzed against water, lyophilized, and ultracentrifuged
at high speed, and the purified LOS was stored at 220°C in PBS.
HPLC analysis for sialic acid quantification. HPLC analysis for sialic acid quantification was per-
formed as previously reported (130) with some modifications. Briefly, purified LOS was incubated with 2
N acetic acid for 3 h at 65°C to release the glycosidically bound Sia. Following acid hydrolysis, the sam-
ples were derivatized using 1,2-diamino-4, 5-methylenedioxybenzene dihydrochloride (DMB) for 2.5 h at
50°C in the dark. Derivatized samples were next filtered through 10K spin columns (Millipore), and the si-
alic acid contents were detected with Dionex UltiMate 3000 HPLC system using a Phenomenex Gemini
C18 column. The excitation and emission signals used for the detection were 373 nm and 448 nm,
respectively.
Detection of free sialic acids. Homogenates from murine tissues were thawed on ice and spun at
20,000 rpm for 10min at 4°C to precipitate the cellular debris. Twenty-five microliters of the supernatant
was then derivatized using DMB at 4°C for 48 h in the dark (131). At the end of incubation, the derivat-
ized samples were filtered through 10K spin column to eliminate any residual debris and detected using
a HPLC machine as described above.
Bacterial growth curve. Frozen cultures were struck onto chocolate II agar and incubated overnight
at 37°C in 5% CO2 (vol/vol). Individual colonies were inoculated in chemically defined media for 2 h at
37°C in 200 rpm. The starter culture was diluted to an optical density (OD600) of 0.05, and the bacteria
were then grown in the presence or absence of 100 mM sialic acid. To determine growth, the OD600 of
the bacterial culture was measured every 30min for 8 h.
Serum bactericidal assay. The bactericidal activity of serum was determined as described previ-
ously (85). Briefly, mid log phase bacteria, grown in the presence or absence of Sia, were centrifuged
at 10,000 rcf for 5min and washed with prewarmed HBSS. The bacteria were resuspended at OD600 of
0.1 in HBSS with 0.1% bovine serum albumin (BSA) and plated on chocolate agar plate following serial
dilution (t= 0). To determine the sensitivity against normal human serum, 10ml of the resuspended
bacteria was treated with 10% pooled normal human sera (NHS) (Complement Technology) and incu-
bated at 37°C, shaking with 200 rpm for 30min. Following incubation, the bacteria were serially
diluted and plated on chocolate agar (t= 30). Resistance to the serum killing was calculated by deter-
mining the viable bacterial count at t= 30 relative to t= 0. The assay was repeated thrice, and for each
individual assay, the appropriate sialylation of the bacteria was determined by ECA lectin binding as
described above.
Whole blood killing assay. For this study, venous blood was collected from healthy donors follow-
ing informed consent in accordance with the guidelines issued by the Institutional Review Board (IRB
170921), University of California, San Diego (UCSD). The whole blood killing assay was done based on
reference 94 with the following modifications. The Sia-fed or unfed bacteria were grown to mid log
phase, washed, and resuspended to an OD600 of 0.1 in HBSS with 0.1% BSA. The resuspended bacteria
were serially diluted and plated on chocolate agar (t= 0). To determine the effect of whole blood on sur-
vival, the bacteria were diluted 1:10 in freshly collected human blood and incubated at 37°C for 30min
with gentle rotation. Following incubation, the bacteria were serially diluted and grown on chocolate
agar (t= 30). The percentage of whole blood killing was calculated as the serum bactericidal assay stated
above. The assay was repeated with multiple individual blood samples, which were freshly collected in
hirudin anticoagulant-containing tubes (Sarstedt).
Purification of recombinant, soluble Fc-chimeric Siglec proteins. Siglec proteins were purified as
described previously (132). Briefly, culture supernatant from transiently transfected HEK293 cells was col-
lected and incubated with Sepharose protein A Column (GE Healthcare Life Sciences) at 4°C for purifica-
tion of the soluble Fc-chimeric proteins. After washing with Tris-buffered saline and desialylation with
Arthrobacter ureafaciens (Sigma) sialidase to eliminate endogenous sialylation, the Siglec-Fc proteins
were eluted with 0.1 M glycine-HCl (pH 3.0) and immediately neutralized using Tris-HCl. The stability of
the purified proteins was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE).
Flow cytometry for C3c, IgM, IgG factor H domain 6 and 7 deposition and Siglec-92Fc binding.
Experiments were performed based on methods described previously (133). Briefly, mid log phase bacte-
ria grown in the presence or absence of Sia were washed in HBSS containing Ca/Mg and then treated
with 10% NHS for 5min at 37°C and 200 rpm. For IgG and IgM deposition, NHS was heat inactivated by
incubation at 56°C for 30min and 200 rpm shaking. Heat-inactivated NHS-treated bacteria were incu-
bated with R-phycoerythrin- or FITC-conjugated antibodies against human IgG and IgM (both Sigma-
Aldrich), respectively. For complement component, C3c was probed with FITC-conjugated anti-human
C3c (Bio-Rad). For factor H 6/7 binding, the bacteria were incubated with the purified FH6/7 (mouse IgG)
supernatant (134) for 30min and visualized using allophycocyanin (APC)-conjugated anti-mouse IgG.
Siglec-92Fc binding was determined by incubating the bacteria with 300 ng of purified protein for 2 h
at 37°C. The visualization was done using Alexa Fluor 488-conjugated secondary antibody against
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human Fc. All the data were collected using BD FACSCalibur flow cytometer, and the data were analyzed
using FlowJo software.
Animal care. All animal experiments were conducted under veterinary supervision and approved by
the University of California, San Diego Institutional Animal Care and Use Committee (IACUC). Eight- to
10-week-old male and female C57BL/6 and Cmah2/2 (109) mice were bred and maintained in a specific-
pathogen-free UCSD animal facility to eliminate any variability introduced by microbiome differences
between breeding facilities. Mice were allowed to eat and drink ad libitum. All efforts were made to min-
imize suffering of animals employed in this study.
In vivo intranasal infection of mice. For intranasal infection of mice, NTHi 2019 was grown as
described above and washed with prewarmed HBSS. Eight- to 10-week-old male and female mice were
anesthetized with isoflurane and infected intranasally with 4  108 to 5 108 CFU in 25ml HBSS.
Twenty-four hours postinfection, mice were humanely euthanized via CO2 asphyxiation. Trachea and
lungs were removed and homogenized in HBSS using a MagNa lyser (Roche). Organ lysates were serially
diluted and plated for bacterial CFU enumeration on selective chocolate agar (Remel) incubated at 37°C
with CO2 for 24 h.
Sialoglycan microarray. Chemoenzymatically synthesized sialoglycans were quantitated utilizing
DMB-HPLC analysis, and glycans were dissolved in 300mM sodium phosphate buffer (pH 8.4) to the final
concentration of 100mM. NHS-functionalized glass slides (PolyAn 3D-NHS slides from Automate
Scientific) were printed with the sialoglycans using a ArrayIt SpotBot Extreme instrument. The method
described previously (56) was used with the following modifications. Each glycan was printed in quadru-
plets. The temperature (20°C) and humidity (70%) inside the ArrayIt printing chamber was thoroughly
maintained during the printing process. The slides were left for drying for an additional 8 h. Printed gly-
can microarray slides were blocked with prewarmed 0.05 M ethanolamine solution (in 0.1 M Tris-HCl [pH
9.0]), washed with warm Milli-Q water, dried, and then fitted in a multiwell microarray chamber (Grace
Bio-Labs) to divide into 16 subarrays. Each subarray well was treated with 200ml of ovalbumin (1% [wt/
vol]) dissolved in freshly prepared PBS buffer (pH 7.4) for 1 h at ambient temperature in a humid cham-
ber with gentle shaking. Subsequently, 200ml of serum solution (1:250 dilution for IgG and 1:50 dilution
for IgM detection) was added to the subarray. After incubating for 2 h at room temperature with gentle
shaking, the slides were extensively washed and treated with fluorophore-conjugated secondary anti-
bodies. Goat anti-human IgG and IgM conjugated to Cy3 and Cy5, respectively (Jackson ImmunoResearch)
were used. Finally, the microarray slides were dried and scanned with a Genepix 4000B (Molecular Devices
Corp., Union City, CA) microarray scanner (at 532/635nm) and data analysis using the Genepix Pro 7.3 analysis
software and plotted in Microsoft Excel.
Human serum samples. The human serum samples from mothers and children at birth and 3, 6,
and 12 months old used in the sialoglycan microarray experiments were the same as previously pub-
lished (48). The sera were collected previously in accordance with the approved protocols of University
of La Frontera, Temuco, Chile, Institutional Review Board and Regional Ethical Committee of the Chilean
National Health Service for the Araucania Region. On the basis of the dietary history, the mothers during
their pregnancy and in the first months during breast feeding routinely consumed plant products like
apples, peaches, tomatoes, avocados, lettuce, cranberries, blueberries, broccoli, eggplant—all of which
are rich sources of dietary mannose. The children fed only on mother’s milk and did not receive any
mammalian meat during the first 3 months. All the samples were completely anonymized and deidenti-
fied prior to receiving the samples at UCSD for the studies.
Human blood for all the assays involving the sera and whole blood were collected from healthy
adult volunteers with informed consent in accordance with the approved institutional protocols of
UCSD human research protections program (IRB 170921). The commercially available pooled normal
human IVIG used in the glycan binding, serum killing, and immune factor interaction studies were
bought from Complement Technology and used with appropriate safety precautions.
Statistical analysis. Statistical significance was determined with GraphPad Prism version 8 software
mainly using one-way analysis of variance (ANOVA) with Tukey multiple comparison test, nonparametric
Mann-Whitney test, or two-tailed paired Student t test as stated in the figure legends, unless mentioned
otherwise. The statistical analysis of the mouse infection data (Fig. 9D to F and Fig. 10A and B) was done
using nonparametric Mann-Whitney test.
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